Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.
Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.
Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.
CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.
CVRx, a commercial-stage medical device company, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. The company will hold a conference call at 5:30 p.m. Eastern Time to discuss the results. Investors can join by dialling (833) 730-3980 for U.S. callers or +1 (720) 405-2140 internationally, referencing conference code 2879175. The FDA-approved Barostim™ device is designed to improve heart failure symptoms by stimulating the body's baroreceptors.
CVRx reported preliminary fourth quarter 2021 revenues of approximately $3.6 million to $3.7 million, a 71% to 77% increase from Q4 2020. Full year 2021 revenue is projected at $13.0 million to $13.1 million, reflecting a 113% to 116% growth from 2020. The company had 46 active implanting centers and reported cash and equivalents of $142 million. For 2022, CVRx anticipates total revenue between $20 million and $23 million with operating expenses of $55 million to $61 million. Despite challenges in Europe, the U.S. heart failure sector shows resilience.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 pm ET. The presentation will be available via a live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. CVRx is known for its FDA-approved Barostim device that alleviates symptoms of heart failure through electrical pulses to baroreceptors, receiving both FDA Breakthrough Device designation and CE Mark approval.
CVRx, a medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The management team's pre-recorded fireside chat is scheduled for November 22, 2021, at 10:00 a.m. ET, accessible via their investor relations page at ir.cvrx.com.
CVRx is known for Barostim™, the first FDA-approved device using neuromodulation to alleviate heart failure symptoms, receiving both the FDA Breakthrough Device designation and CE Mark for its effectiveness.
CVRx reported Q3 2021 revenue of $3.4 million, a notable 241% increase year-over-year. U.S. heart failure revenue surged to $2.5 million from $0.1 million in the prior year. The company successfully closed its IPO in July 2021, raising net proceeds of approximately $133.2 million, and has since fully repaid a $20 million loan. The outlook for 2021 remains positive, with projected revenue between $13.3 million and $13.9 million. Additionally, CVRx filed three PMA Supplement applications with the FDA to enhance its Barostim platform.
CVRx, a medical device company, will release its third quarter financial results on November 4, 2021, after market close. A conference call to discuss these results is scheduled for 5:30 p.m. Eastern Time the same day. U.S. callers can dial (833) 730-3980, while international callers should use +1 (720) 405-2140, referencing conference code 6038756. CVRx is known for developing Barostim™, an FDA-approved neuromodulation device that helps heart failure patients by restoring balance to the autonomic nervous system.
CVRx, a commercial-stage medical device company, announced its inclusion in the Russell 2000® and 3000® Indexes, effective September 20, 2021. This addition, shortly after their IPO, highlights the company's progress in advancing the commercial adoption of Barostim™, a neuromodulation solution for heart failure. CEO Nadim Yared expressed optimism about the increased visibility and awareness for their therapy resulting from this inclusion in widely used Russell indexes, which manage approximately $10.6 trillion in assets.
CVRx reported a 150% increase in revenue for Q2 2021, totaling $3.1 million. U.S. heart failure revenue surged to $2.0 million from $65,000 year-over-year. The company successfully closed its IPO on July 2, 2021, raising $133.3 million. Gross profit rose to $2.2 million, yet gross margin fell to 70.8%. Notably, net loss expanded to $17.7 million, driven by increased expenses related to stock warrants. The company anticipates full-year revenue between $13.3 million and $13.9 million.
CVRx announced its participation in the Canaccord Genuity 41st Annual Growth Conference scheduled for August 12, 2021 at 11:00 am ET. The management team will present via a live audio webcast accessible on the company's investor relations webpage. The presentation will also be archived for 90 days. CVRx focuses on minimally invasive solutions for cardiovascular diseases, notably the Barostim, which is FDA-approved for treating heart failure.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will release its second quarter financial results on August 4, 2021, after market close. A conference call to discuss the results is scheduled for 5:30 p.m. ET the same day. Participants can join via telephone or listen to a live webcast available on the CVRx investor website. CVRx's Barostim device, which treats heart failure by sending electrical pulses to baroreceptors, has received FDA approval and Breakthrough Device designation.